|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 14 amino acid peptide from near the amino terminus of human Bfl-1.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Western Blot (WB)||1-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
Despite the predicted molecular weight, Bfl-1 often migrates at a higher molecular weight in SDS-PAGE, presumably due to post-translational modifications. A suggested positive control is mouse kidney tissue lysate.
PA5-20269 can be used with blocking peptide PEP-0384.
Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells and is caused by caspase activation. Proteins that comprise the Bcl-2 family appear to control the activation of these enzymes. One such member is multi-domain antiapoptotic protein Bfl-1, which is overexpressed in stomach and other cancers. Bfl-1 can interact with Bax and suppress apoptosis by inhibiting the release of cytochrome c and caspase-3 activation. It is upregulated in cisplatin-resistant human bladder tumors, suggesting that its expression may be important for cisplatin resistance and inhibition of apoptosis in cancer cells. At least two isoforms of Bfl-1 are known to exist.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
PA5-20269 was used in western blot to investigate the effect of antimesothelin immunotoxin SS1P and BH3-mimetic ABT-737 on SS1P-resistant pancreatic cancer cells
|Hollevoet K,Antignani A,Fitzgerald DJ,Pastan I||Journal of immunotherapy (Hagerstown, Md. : 1997) (37:8)||2014|